---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-286642"
form_type: "8-K"
ticker: "HCWB"
cik: "0001828673"
company_name: "HCW Biologics Inc."
filed_at: "2025-11-19T23:59:59+00:00"
generated_at: "2026-05-16T18:31:18.657909+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# HCW Biologics licenses HCW11-006 to Trimmune; $7M upfront (half cash, half equity)

## Summary
- Amended License, Research & Co-Development Agreement with Beijing Trimmune for HCW11-006 in vivo applications.
- $7.0M upfront fee: $3.5M cash at closing, $3.5M in Trimmune equity.
- Company retains payment-free option to recapture rights for US, Canada, Central & South America after Phase 1.
- Trimmune responsible for all R&D, manufacturing, clinical, regulatory, commercialization costs in its territory.
- If closing not completed by Jan 16, 2026, all IP and rights to HCW11-006 return to HCW.

## SEC filing metadata
- accession: 0001193125-25-286642
- form_type: 8-K
- ticker: HCWB
- cik: 0001828673
- company_name: HCW Biologics Inc.
- filed_at: 2025-11-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828673/000119312525286642/0001193125-25-286642-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828673/000119312525286642/hcwb-20251117.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-286642
- JSON: https://secwatch.observer/filing/0001193125-25-286642.json
- Plain text: https://secwatch.observer/filing/0001193125-25-286642.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.